Smart Trade Insights
  • Business
  • Economy
  • Investing
  • Politics
Top Posts
Lithium Africa
Kalgoorlie Gold Mining
Juggernaut Exploration
Skyharbour Resources
LaFleur Minerals
Grande Portage Closes Non-Brokered Private Placement Pursuant to...
Brunswick Exploration Announces AGM Results
Harvest Gold Announces Annual General Meeting Results
Editor’s Picks: Trump to Lift Minnesota Mining Ban,...
Crypto Market Recap: Stablecoin Market Makes Headway, SharpLink...
  • Business
  • Economy
  • Investing
  • Politics

Smart Trade Insights

Investing

Positive results from Phase 2 Sleep Signal Analysis for Current Major Depressive Episode (SAMDE) Study

by admin August 14, 2024
August 14, 2024
Positive results from Phase 2 Sleep Signal Analysis for Current Major Depressive Episode (SAMDE) Study

TrivarX Limited (‘the Company’) (ASX: TRI) is pleased to announce positive top-line results from the Company’s recently completed Phase 2 Sleep Signal Analysis for Current Major Depressive Episode (SAMDE) study utilising its proprietary AI-backed algorithm, MEB-001. MEB-001 uses EEG and ECG signals recorded during sleep to identify current Major Depressive Episode (cMDE).

Highlights:

Analysis of 400 patients in Phase 2 SAMDE study for current Major Depressive Episode (cMDE) study utilising MEB-001MEB-001 is TrivarX’s proprietary AI-driven algorithm which can assist with the effective screening of a cMDEMEB-001 performance results from Phase 2 SAMDE study reported high performance, marking a significant achievement in the Company:Sensitivity: 87% (95% CI 73-95%)Specificity: 72% (95% CI 66-77%)Positive Predictive Value: 35% (95% CI 27-45%)Negative Predictive Value: 97% (95% CI 93-99%)Results provide strong validation of MEB-001’s ability to assist in the screening and diagnosis of a cMDE – a condition which is commonly misdiagnosedThere is currently no screening undertaken for cMDE in sleep centres in the US or globally, representing a major commercial opportunity for TrivarXResults advance TRI’s aim to become the first depression screening tool used in clinical practice in sleep centres

There is a well-established connection between mental health conditions, such as depression, and sleep disturbances. People with insomnia may have a tenfold higher risk of developing cMDE and among people with depression, 75% of sufferers have trouble falling or staying asleepi. Furthermore, misdiagnosis of major depressive disorder is estimated at upwards of 65% in the USii. Despite this, depression screening is not routinely included in sleep studies, even though up to 21% of people undergoing a sleep study have depressioniii.

Positive results from SAMDE study highlight MEB-001’s significant potential:

The objective of the study (ClinicalTrials.gov ID NCT05708222) was to use MEB-001 to detect the likelihood of a cMDE using Clinician Reporting Outcomes (CRO) assessment in individuals referred to a sleep clinic. A total of 400 patients were recruited across 15 sleep centres in the US. Out of these, 73 patients were excluded due to incomplete data or a split night/titration sleep study. MEB-001 also automatically identified 32 patients with significant anomalies in their sleep data. Notably, the MEB-001 algorithm was locked prior to the analysis ensuring no data from Phase 2 was used in its training.

Analysis of the results showed that MEB-001 reported promising performance across key parameters including sensitivity of 87% (95% CI 73-96%), specificity of 72% (95% CI 66-77%), positive predictive value (PPV) of 35% (95% CI 27-45%) and negative predictive value (NPV) of 97% (95% CI 93-99%) (refer table below).

These results provide considerable validation of MEB-001 and its ability in the screening and diagnosis of a current Major Depressive Episode (cMDE) in test subjects.

Management commentary:

Non-executive Chairman, David Trimboli said: “We are very excited to share the results from our Phase2 study, which highlight the effectiveness of MEB-001 in screening for cMDE. This is underscored by the significant increase in sensitivity coming from recent improvements to the underlying algorithm, which was increased from 71% in Phase 1, to 87% in Phase 2 – demonstrating that the algorithm can successfully identify more people with cMDE. Our very high NPV validates MEB-001’s potential as a screening test, with the likelihood of having depression when testing negative to be less than 3%.

“There is currently no screening undertaken for cMDE in sleep centres in the US or globally. Our most recent results reaffirm the potential of MEB-001 to become the first depression screening tool used in clinical practice in sleep centres and marks a significant achievement in the Company’s history.”

Click here for the full ASX Release

This post appeared first on investingnews.com

previous post
Barrick CEO Bristow Expects Strong H2 After Delivering Latest Quarterly Results
next post
American Rare Earths Forges a New Path to Accelerate Development of Key Wyoming Asset

You may also like

5 Biggest Blockchain ETFs in 2025

June 4, 2025

Trump Administration Strikes 50/50 Minerals Deal with Ukraine

May 2, 2025

Don Hansen: Gold, Silver Stocks “Extraordinarily Undervalued,” Data...

December 24, 2024

Condor Energies Secures Second Critical Minerals Mining License...

March 12, 2025

Retraction of Lo Herma Scoping Study Statements

June 6, 2025

AI Market Update: Q1 2025 in Review

April 10, 2025

Excellent Metallurgical Results at Hotinvaara Enhance Entire Pulju...

October 23, 2024

Equinox Gold and Calibre Mining to Join Forces...

February 25, 2025

CEOL Application and Amended 2024 Interim Results for...

January 2, 2025

Fabi Lara: Uranium Thesis is Back, How to...

January 29, 2025

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Lithium Africa

      June 14, 2025
    • Kalgoorlie Gold Mining

      June 14, 2025
    • Juggernaut Exploration

      June 14, 2025
    • Skyharbour Resources

      June 14, 2025
    • LaFleur Minerals

      June 14, 2025
    Promotion Image

    banner ads

    Categories

    • Business (720)
    • Economy (829)
    • Investing (2,201)
    • Politics (737)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: smarttradeinsights.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 smarttradeinsights.com | All Rights Reserved